


Global Health

We are committed to address challenges that **affects millions of people**, improving the **health** of underserved populations in **low- and middle-income countries** through our **science & technology** innovations and products, and in close collaboration with our **partners**.



our impact

For society and sustainable business value for our Company

- Innovative solutions** that address unmet medical needs of the developing world
- Partnerships** to amplify impact and shape progress of the Sustainable Development Goals
- Sustainable business models** to ensure that our assets and investments reach the unserved and underserved populations, regardless of their ability to pay

Through our efforts and investments, we contribute to the **United Nations Sustainable Development Goals** that are embedded into the **Company's Sustainability Strategy**.

UN Sustainable Development Goals



Company's Sustainability Strategy

01 dedicated to human progress

In 2030, we will achieve human progress for more than one billion people through sustainable science and technology.

Our focus areas

- Sustainable innovations and technology for our customers
- Impact of our technologies and products on health and wellbeing

Focus SDGs 3 8 9 17

02 creating sustainable value chains

By 2030, we will integrate sustainability into all our value chains.

Our focus areas:

- Sustainability culture and values
- Sustainable and transparent supply chain
- Securing our social license to operate in all regions

Focus SDGs 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17

03 reducing our ecological footprint

By 2040, we will achieve climate neutrality and reduce our resource consumption.

Our focus areas:

- Climate change and emissions
- Water and resource intensity

Focus GHG 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17

Our Global Health Strategic Priorities



Expand access to our healthcare portfolio in low- and middle-income countries (LMICs)



Drive integrated schistosomiasis elimination as a public health problem



Catalyze innovative solutions for global health challenges

Access to our products & technologies to patients in need in LMICs

Our 3As Approach to Access

Availability → Accessibility → Affordability

Driving the development of solutions to address health challenges, using needs-based Research & Development and responsible Intellectual Property while planning for fastest and broadest access to innovation.

Strengthening health services and infrastructure in low- and middle-income countries to enable patient access to the best possible care.


Implementing innovative mechanisms for equitable and sustainable access to our innovations and products.

Our company's ambition is to improve lives of more than 170 million patients per year in low- and middle-income countries by 2030.



How we fight Schistosomiasis

our goal: elimination of schistosomiasis as a public health problem through an integrated approach



2007

Begin of the donation program in partnership with WHO

Up to 250 Millions

PZQ tablets committed annual donation

>1.9 Billion

PZQ tablets provided since the beginning of the program

>750 Millions

Treatments of patients mainly school-aged children

47

African countries supplied

>10

R&D projects for innovative products and technologies

>30

R&D partnerships



Update: Sep 2023

How we fight Malaria

our goal: prevention and control of malaria worldwide



>200 Millions

Cases of malaria worldwide

600,000

Deaths worldwide

95%

Deaths in Africa

80%

Deaths in children under five

Treatment
Drug discovery & clinical development for new anti-malarials

Resilience of Health Systems

Tools to access to essential resources and strengthen capacities

Prevention and control of malaria

Prevention
IR3535[®] insect repellent against malaria

Diagnosis
Programs to foster workforce capabilities

